
Justin L Grodin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8330133/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19. Circulation, 2021, 143, 135-144.	1.6	230
2	Phenomapping of patients with heart failure with preserved ejection fraction using machine learningâ€based unsupervised cluster analysis. European Journal of Heart Failure, 2020, 22, 148-158.	7.1	169
3	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care, 2019, 42, 2298-2306.	8.6	157
4	Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2015, 66, 659-666.	2.8	123
5	Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis. Circulation, 2022, 145, 1123-1139.	1.6	118
6	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	4.1	104
7	In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation, 2021, 144, 487-498.	1.6	102
8	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, e002453.	3.9	61
9	ATTR Amyloidosis: Current and Emerging Management Strategies. JACC: CardioOncology, 2021, 3, 488-505.	4.0	56
10	Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	3.7	51
11	Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a perâ€protocol analysis of CARRESSâ€HF. European Journal of Heart Failure, 2018, 20, 1148-1156.	7.1	51
12	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2016, 22, 26-32.	1.7	48
13	A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. American Heart Journal, 2015, 169, 806-812.	2.7	44
14	Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). American Journal of Cardiology, 2017, 119, 78-83.	1.6	44
15	Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. European Journal of Heart Failure, 2019, 21, 634-642.	7.1	42
16	Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis. Circulation, 2022, 145, 18-20.	1.6	41
17	Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. JACC: Heart Failure, 2016, 4, 923-931.	4.1	40
18	Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016. JAMA Network Open, 2020, 3, e2022190.	5.9	38

JUSTIN L GRODIN

#	Article	IF	CITATIONS
19	Prognostic Comparison of Different Sensitivity Cardiac Troponin Assays in Stable Heart Failure. American Journal of Medicine, 2015, 128, 276-282.	1.5	37
20	Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. European Journal of Heart Failure, 2015, 17, 689-696.	7.1	35
21	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 2016, 22, 884-890.	1.7	35
22	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. Diabetes Care, 2020, 43, 1920-1928.	8.6	35
23	Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clinical Biochemistry, 2017, 50, 491-495.	1.9	34
24	Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4449-4458.	3.6	33
25	Generalizability and Implications of the H ₂ FPEF Score in a Cohort of Patients With Heart Failure With Preserved Ejection Fraction. Circulation, 2019, 139, 1851-1853.	1.6	32
26	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. Journal of Cardiac Failure, 2018, 24, 428-438.	1.7	31
27	Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. European Journal of Heart Failure, 2018, 20, 1436-1443.	7.1	31
28	Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Failure Reviews, 2021, 26, 35-45.	3.9	27
29	Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. ESC Heart Failure, 2021, 8, 842-848.	3.1	24
30	Insufficient reduction in heart rate during hospitalization despite betaâ€blocker treatment in acute decompensated heart failure: insights from the ASCENDâ€HF trial. European Journal of Heart Failure, 2017, 19, 241-249.	7.1	22
31	Transient Hyponatremia During Hospitalization for Acute Heart Failure. American Journal of Medicine, 2016, 129, 620-627.	1.5	19
32	Unique Patterns of Cardiovascular Involvement in Coronavirus Disease-2019. Journal of Cardiac Failure, 2020, 26, 466-469.	1.7	17
33	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676.	1.7	16
34	Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure. Current Heart Failure Reports, 2016, 13, 181-189.	3.3	15
35	Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007931.	3.9	15
36	Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from) Tj ETQq0 0 () rgBT /Over	lock 10 Tf 50

JUSTIN L GRODIN

#	Article	IF	CITATIONS
37	Dilemmas in the Dosing of Heart Failure Drugs: Titrating Diuretics in Chronic Heart Failure. Cardiac Failure Review, 2017, 3, 108.	3.0	13
38	Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. Journal of Cardiac Failure, 2018, 24, 542-549.	1.7	13
39	Identifying a lowâ€flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial. ESC Heart Failure, 2019, 6, 613-620.	3.1	13
40	Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: From the Dallas Heart Study. Vascular Medicine, 2011, 16, 339-345.	1.5	12
41	Diuretic Strategies in Acute Decompensated Heart Failure. Current Heart Failure Reports, 2017, 14, 127-133.	3.3	12
42	Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. International Journal of Cardiology, 2018, 252, 112-116.	1.7	12
43	Angiotensin Receptor–Neprilysin Inhibitors and the Natriuretic Peptide Axis. Current Heart Failure Reports, 2020, 17, 67-76.	3.3	12
44	Impact of Ultrafiltration on Serum Sodium Homeostasis and its Clinical Implication in Patients With Acute Heart Failure, Congestion, and Worsening Renal Function. Circulation: Heart Failure, 2017, 10, e003603.	3.9	11
45	Prognostic Implications of Changes in Amino-Terminal Pro–B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. Journal of Cardiac Failure, 2019, 25, 703-711.	1.7	11
46	Relationship between novel inflammatory biomarker galectin-3 and depression symptom severity in a large community-based sample. Journal of Affective Disorders, 2021, 281, 384-389.	4.1	11
47	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESSâ€HF. Journal of the American Heart Association, 2020, 9, e015752.	3.7	11
48	Hyperkalemia in Heart Failure: Probably Not O"K― Journal of the American Heart Association, 2018, 7, .	3.7	10
49	Treatment Strategies for the Prevention of Heart Failure. Current Heart Failure Reports, 2013, 10, 331-340.	3.3	9
50	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2018, 24, 512-519.	1.7	9
51	Sex differences in cardiac function, biomarkers and exercise performance in heart failure with preserved ejection fraction: findings from the RELAX trial. European Journal of Heart Failure, 2019, 21, 1476-1479.	7.1	9
52	The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis. Circulation, 2019, 140, 27-30.	1.6	9
53	Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure. Circulation, 2020, 142, 1055-1058.	1.6	9
54	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.6	9

Justin L Grodin

#	Article	IF	CITATIONS
55	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and HeartÂFailure Risk in Black Adults. JACC: Heart Failure, 2022, 10, 129-138.	4.1	9
56	Response by Hendren et al to Letter Regarding Article, "Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry― Circulation, 2021, 144, e8-e9.	1.6	8
57	Variation of heart transplant rates in the United States during holidays. Clinical Transplantation, 2014, 28, 877-882.	1.6	6
58	Implications of reninâ€angiotensinâ€system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. Clinical Cardiology, 2019, 42, 1010-1018.	1.8	6
59	Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis. Current Heart Failure Reports, 2020, 17, 77-83.	3.3	6
60	Identifying Discordance of Right- and Left-Ventricular Filling Pressures in Patients With Heart Failure by the Clinical Examination. Circulation: Heart Failure, 2021, 14, e008779.	3.9	6
61	Severe COVID-19 vaccine associated myocarditis: Zebra or unicorn?. International Journal of Cardiology, 2021, 343, 197-198.	1.7	6
62	Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population. Journal of Cardiac Failure, 2022, 28, 403-414.	1.7	5
63	Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population. American Journal of Cardiology, 2022, 167, 98-103.	1.6	5
64	Epidemiology and risk factors for varicella zoster virus reactivation in heart transplant recipients. Transplant Infectious Disease, 2020, 23, e13519.	1.7	4
65	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 297-308.	1.7	4
66	Discordance Between Severity of Heart Failure as Determined by Patient Report Versus Cardiopulmonary Exercise Testing. Journal of the American Heart Association, 2021, 10, e019864.	3.7	4
67	Worsening Heart Failure. JACC: Heart Failure, 2015, 3, 404-407.	4.1	3
68	I will take my heart failure â€~lactateâ€free' please. European Journal of Heart Failure, 2018, 20, 1019-1020.	7.1	3
69	Implications of Perceived Dyspnea and Global Well-Being Measured by Visual Assessment Scales During Treatment for Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 402-408.	1.6	3
70	Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial. European Journal of Heart Failure, 2019, 21, 693-695.	7.1	3
71	Delayed febrile response with bloodstream infections in patients with continuous-flow left ventricular assist devices. Journal of Investigative Medicine, 2019, 67, 653-658.	1.6	3
72	Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with betaâ€blockers. ESC Heart Failure, 2020, 7, 3049-3058.	3.1	3

Justin L Grodin

#	Article	IF	CITATIONS
73	Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS. Journal of the American Heart Association, 2020, 9, e016203.	3.7	3
74	Finding Mentorship Among Your Peers. Journal of the American College of Cardiology, 2016, 68, 2585-2587.	2.8	2
75	Intensive Blood Pressure Control and Body Size. Journal of the American College of Cardiology, 2018, 72, 1317-1318.	2.8	2
76	Lung Ultrasound. JACC: Heart Failure, 2019, 7, 859-861.	4.1	2
77	Subclinical Myocardial Injury and the Phenotype of Clinical Congestion in Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 422-430.	1.7	2
78	Phenomapping a Novel Classification System for Patients With Destination Therapy Left Ventricular Assist Devices. American Journal of Cardiology, 2021, , .	1.6	2
79	Left Ventricular Assist Device Implantation and Kidney Function: Chicken, Egg, or Omelet?. Kidney Medicine, 2021, 3, 324-326.	2.0	1
80	Hemodynamically, the kidney is at the heart of cardiorenal syndrome. Cleveland Clinic Journal of Medicine, 2018, 85, 240-242.	1.3	1
81	Impact of body mass index on surgical coronary revascularization for ischaemic heart failure: insights from STICHES. ESC Heart Failure, 2020, 7, 4390-4393.	3.1	1
82	Novel Biomarkers of Heart Failure: Do They Have Incremental Clinical Utility?. Journal of Cardiac Failure, 2016, 22, 263-264.	1.7	0
83	Driving with the headlights on: Measuring adequate urinary sodium excretion on the road to precision diuresis. American Heart Journal, 2018, 203, 93-94.	2.7	0
84	Myocardial dysfunction in breast cancer survivors: â€~you can observe a lot by just watching'. European Journal of Heart Failure, 2020, 22, 347-349.	7.1	0
85	Uncommon Disease in a Rare Location. Circulation, 2020, 142, 1591-1595.	1.6	0
86	Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?. European Journal of Heart Failure, 2022, 24, 1077-1079.	7.1	0